Pluristem Therapeutics Inc. (NASDAQ:PSTI) went up by 14.57% from its latest closing price compared to the recent 1-year high of $13.29. The company’s stock price has collected 19.92% of gains in the last five trading sessions. Press Release reported on 01/06/21 that Pluristem Announces Appointments of Two Directors to Board
Is It Worth Investing in Pluristem Therapeutics Inc. (NASDAQ :PSTI) Right Now?
Plus, the 36-month beta value for PSTI is at 2.49. Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for Pluristem Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $8.60, which is $0.11 above the current price. PSTI currently public float of 20.52M and currently shorts hold a 5.19% ratio of that float. Today, the average trading volume of PSTI was 427.22K shares.
PSTI’s Market Performance
PSTI stocks went up by 19.92% for the week, with a monthly jump of 21.29% and a quarterly performance of -23.72%, while its annual performance rate touched 100.24%. The volatility ratio for the week stands at 12.66% while the volatility levels for the past 30 days are set at 9.14% for Pluristem Therapeutics Inc.. The simple moving average for the period of the last 20 days is 26.26% for PSTI stocks with a simple moving average of -3.51% for the last 200 days.
Analysts’ Opinion of PSTI
Many brokerage firms have already submitted their reports for PSTI stocks, with Jefferies repeating the rating for PSTI by listing it as a “Hold.” The predicted price for PSTI in the upcoming period, according to Jefferies is $6 based on the research report published on December 10th of the previous year 2020.
Jefferies, on the other hand, stated in their research note that they expect to see PSTI reach a price target of $12. The rating they have provided for PSTI stocks is “Buy” according to the report published on June 19th, 2020.
Dawson James gave a rating of “Buy” to PSTI, setting the target price at $12 in the report published on December 16th of the previous year.
PSTI Trading at 0.75% from the 50-Day Moving Average
After a stumble in the market that brought PSTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.12% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 12.66%, as shares surge +36.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.12% lower at present.
During the last 5 trading sessions, PSTI rose by +19.92%, which changed the moving average for the period of 200-days by +161.23% in comparison to the 20-day moving average, which settled at $6.84. In addition, Pluristem Therapeutics Inc. saw 20.08% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PSTI starting from CLOVER WOLF CAPITAL – LIMITED , who purchase 20,000 shares at the price of $9.70 back on Nov 30. After this action, CLOVER WOLF CAPITAL – LIMITED now owns 4,077,589 shares of Pluristem Therapeutics Inc., valued at $194,000 using the latest closing price.
CLOVER WOLF CAPITAL – LIMITED , the 10% Owner of Pluristem Therapeutics Inc., purchase 50,000 shares at $9.51 during a trade that took place back on Oct 30, which means that CLOVER WOLF CAPITAL – LIMITED is holding 4,057,589 shares at $475,500 based on the most recent closing price.
Stock Fundamentals for PSTI
Current profitability levels for the company are sitting at:
- -128156.52 for the present operating margin
- -6726.09 for the gross margin
The net margin for Pluristem Therapeutics Inc. stands at -126747.83. The total capital return value is set at -74.15, while invested capital returns managed to touch -74.28. Equity return is now at value -90.30, with -70.80 for asset returns.
Based on Pluristem Therapeutics Inc. (PSTI), the company’s capital structure generated 2.83 points at debt to equity in total, while total debt to capital is 2.75. Total debt to assets is 2.42, with long-term debt to equity ratio resting at 1.01. Finally, the long-term debt to capital ratio is 0.98.
When we switch over and look at the enterprise to sales, we see a ratio of 5,048.27, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.02 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.